Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

AIM: To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20–25% o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Nadia, Said, Amira S. A., Khan, Zainab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933036/
https://www.ncbi.nlm.nih.gov/pubmed/29850259
http://dx.doi.org/10.1155/2018/6106041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933036/
https://www.ncbi.nlm.nih.gov/pubmed/29850259
http://dx.doi.org/10.1155/2018/6106041

Ejemplares similares